chr12-109483612-G-T
Position:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PVS1_StrongPM2PP5_Very_Strong
The NM_130466.4(UBE3B):c.61G>T(p.Glu21Ter) variant causes a stop gained change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.0000124 in 1,612,716 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000026 ( 0 hom., cov: 32)
Exomes 𝑓: 0.000011 ( 0 hom. )
Consequence
UBE3B
NM_130466.4 stop_gained
NM_130466.4 stop_gained
Scores
5
1
1
Clinical Significance
Conservation
PhyloP100: 8.82
Genes affected
UBE3B (HGNC:13478): (ubiquitin protein ligase E3B) The modification of proteins with ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of enzymes: E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes, and E3 ubiquitin-protein ligases. This gene encodes a member of the E3 ubiquitin-conjugating enzyme family which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme and transfers the ubiquitin to the targeted substrates. A HECT (homology to E6-AP C-terminus) domain in the C-terminus of the longer isoform of this protein is the catalytic site of ubiquitin transfer and forms a complex with E2 conjugases. Shorter isoforms of this protein which lack the C-terminal HECT domain are therefore unlikely to bind E2 enzymes. Alternatively spliced transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2012]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant located near the start codon (<100nt), not predicted to undergo nonsense mediated mRNA decay. Fraction of 0.981 CDS is truncated, and there are 2 pathogenic variants in the truncated region.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 12-109483612-G-T is Pathogenic according to our data. Variant chr12-109483612-G-T is described in ClinVar as [Pathogenic]. Clinvar id is 225041.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
UBE3B | NM_130466.4 | c.61G>T | p.Glu21Ter | stop_gained | 3/28 | ENST00000342494.8 | NP_569733.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
UBE3B | ENST00000342494.8 | c.61G>T | p.Glu21Ter | stop_gained | 3/28 | 1 | NM_130466.4 | ENSP00000340596 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152214Hom.: 0 Cov.: 32
GnomAD3 genomes
AF:
AC:
4
AN:
152214
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000440 AC: 11AN: 249934Hom.: 0 AF XY: 0.0000148 AC XY: 2AN XY: 135118
GnomAD3 exomes
AF:
AC:
11
AN:
249934
Hom.:
AF XY:
AC XY:
2
AN XY:
135118
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000110 AC: 16AN: 1460502Hom.: 0 Cov.: 31 AF XY: 0.00000551 AC XY: 4AN XY: 726588
GnomAD4 exome
AF:
AC:
16
AN:
1460502
Hom.:
Cov.:
31
AF XY:
AC XY:
4
AN XY:
726588
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152214Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74356
GnomAD4 genome
AF:
AC:
4
AN:
152214
Hom.:
Cov.:
32
AF XY:
AC XY:
1
AN XY:
74356
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ExAC
AF:
AC:
1
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:6
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Aug 23, 2024 | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 25356970, 31162149, 30792901, 31847883, 24615390, 27535533) - |
Pathogenic, criteria provided, single submitter | clinical testing | Greenwood Genetic Center Diagnostic Laboratories, Greenwood Genetic Center | Jan 22, 2021 | PVS1, PM3, PM2, PS4_Moderate - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 25, 2024 | This sequence change creates a premature translational stop signal (p.Glu21*) in the UBE3B gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in UBE3B are known to be pathogenic (PMID: 23687348, 24615390). This variant is present in population databases (rs775981553, gnomAD 0.03%). This premature translational stop signal has been observed in individual(s) with Kaufman oculocerebrofacial syndrome (PMID: 24615390, 30792901). ClinVar contains an entry for this variant (Variation ID: 225041). For these reasons, this variant has been classified as Pathogenic. - |
Oculocerebrofacial syndrome, Kaufman type Pathogenic:2
Pathogenic, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Dec 12, 2019 | The UBE3B c.61G>T (p.Glu21Ter) variant is a stop-gained variant that is predicted to result in an absent or prematurely truncated protein product, including loss of the functionally critical HECT domain. The p.Glu21Ter variant has been reported in two studies in which it was identified in a homozygous state in two unrelated individuals, one with a diagnosis of Kaufman oculocerebrofacial syndrome and one with blepharophimosis-ptosis-intellectual disability syndrome (Basal-Vanagaite et al. 2014; Farwell et al. 2015). The p.Glu21Ter variant is reported at a frequency of 0.000286 in the Latino population of the Genome Aggregation Database. Based on the collective evidence, the p.Glu21Ter variant is classified as pathogenic for Kaufman oculocerebrofacial syndrome. - |
Pathogenic, criteria provided, single submitter | research | DECIPHERD-UDD, Universidad del Desarrollo | Jul 01, 2023 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 29, 2012 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
Eigen
Pathogenic
Eigen_PC
Pathogenic
FATHMM_MKL
Pathogenic
D
MutationTaster
Benign
A;A;A;A;A;A;A
Vest4
GERP RS
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at